Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin’s U.S. label. The committee’s vote does not affect the current availability of Avastin for people with advanced...
July 20, 2010 – Toxicities associated with bevacizumab (Avastin) appear to be manageable when the drug is delivered as first-line therapy with various chemotherapy combinations to patients with nonsquamous nonsmall-cell lung cancer (NSCLC), report investigators from the international postmarketing study dubbed SAiL (Safety of Avastin in Lung).
In an uncontrolled open-label phase 4 study designed to reassure clinicians about...
July 9 (Bloomberg) -- Vaximm Holding AG, a joint venture between Merck KGaA and a Swiss investment fund, will start testing an experimental cancer vaccine in patients next year.
The 40-person study will give Darmstadt, Germany-based Merck a stake in a second anti-tumor vaccine in human trials. The researchers will recruit patients with advanced pancreatic cancer, with results expected in 12 months, said Klaus Breiner,...
By Crystal Phend, Senior Staff Writer, MedPage Today
Published: June 10, 2010
Bevacizumab (Avastin) substantially increases the risk of kidney damage when added to chemotherapy for cancer patients, a meta-analysis affirmed.
The risk of incident grade 3 or 4 proteinuria more than quadrupled with the combination compared with chemotherapy alone (relative risk 4.79, P<0.001), Shenhong Wu, of the Stony Brook University Cancer Center in Stony Brook, N.Y., and colleagues...
* Unfavourable risk-benefit assessment of adding Avastin
* Standard of care is MabThera plus CHOP chemotherapy
* Findings do not impact Avastin's approved indications
(Adds details, background)
ZURICH, June 3 (Reuters) - Swiss drugmaker Roche Holding AG (ROG.VX) has stopped enrolling patients into a late stage trial for Avastin and MabThera...
